Zepbound, Shaq Target 24M Americans With Sleep Apnea

Eli Lilly taps NBA Hall of Famer Shaquille O'Neal to anchor its "Watch This" campaign for Zepbound — the first FDA-approved drug for moderate-to-severe obstructive sleep apnea in adults with obesity.

Lead

Eli Lilly (LLY) launched its national "Watch This" campaign on June 10, 2026, enlisting Shaquille O'Neal as the public face of Zepbound (tirzepatide) for the treatment of obstructive sleep apnea — a condition the basketball legend was diagnosed with in 2011 yet left largely untreated for over a decade. The multi-channel effort spans broadcast, streaming, digital, social media, and live community events, targeting the estimated 24 million Americans living with moderate-to-severe OSA who remain largely unaware that a prescription treatment option exists.

What Happened

O'Neal disclosed that for years he dismissed chronic daytime fatigue, loud snoring, and difficulty concentrating as inevitable byproducts of his size. His diagnosis came through Harvard Medical School's Division of Sleep Medicine. Treatment with tirzepatide — marketed as Zepbound for obesity and OSA, and as Mounjaro for type 2 diabetes — delivered measurable improvement in both sleep quality and body weight. "For a long time, I was tired during the day, not sleeping well at night, and I just thought that's how it was for someone my size," O'Neal said in campaign materials.

Eli Lilly's Chief Marketing Officer Lina Polimeni described the partnership as a deliberate effort to "break through the stigma and spark real conversations" around OSA — a condition that affects an estimated 77 million Americans by 2050 yet carries significant social and clinical underreporting. The campaign builds on a precursor effort titled "Don't Sleep on OSA," which debuted in October 2025 alongside the dedicated resource site DontSleepOnOSA.com.

Clinical and Regulatory Context

Zepbound received FDA clearance on December 20, 2024, as the first and only prescription medication approved specifically for moderate-to-severe obstructive sleep apnea in adults with obesity — a distinction that separates it from existing mechanical interventions such as continuous positive airway pressure (CPAP) therapy. The pivotal SURMOUNT-OSA trials demonstrated that tirzepatide reduced the apnea-hypopnea index (AHI) — the standard measure of sleep disruption events — by 25.3 to 29.3 events per hour compared with 5.3 to 5.5 events per hour on placebo.

Between 42.2% and 51.5% of trial participants achieved remission or mild OSA without symptoms within one year, versus 13.6% to 16% in the placebo group. Patients also lost 18–20% of body weight on average, or roughly 45 to 50 pounds, over the study period. Adverse events were predominantly mild to moderate gastrointestinal effects, consistent with the broader tirzepatide profile.

Strategic Context

The "Watch This" campaign reflects Eli Lilly's broader effort to expand the addressable market for Zepbound beyond obesity and diabetes. The tirzepatide franchise — Mounjaro and Zepbound combined — generated $36.5 billion in 2025, representing 56% of Lilly's total revenue. Zepbound alone contributed $13.5 billion, with Q4 2025 sales of $4.3 billion, up 123% year-over-year. The drug held 71% of new U.S. obesity prescriptions at quarter-end, outpacing competitor semaglutide products from Novo Nordisk.

By anchoring the OSA campaign around a culturally prominent figure — O'Neal remains one of the most recognizable athletes globally — Lilly targets populations that may be at elevated risk for sleep apnea due to body size or neck anatomy, while simultaneously addressing a diagnostic gap. The 85% undiagnosed rate among OSA sufferers represents a large pool of potential patients who have not been captured by existing clinical pathways.

What Comes Next

Eli Lilly projects 2026 total revenue of $80–83 billion, with non-GAAP earnings per share of $33.50–$35.00. The "Watch This" campaign is positioned as a long-cycle awareness initiative, not a product launch event, suggesting sustained media investment throughout the year. Prescriber education and patient navigation tools will complement the consumer-facing creative. Regulatory expansion of Zepbound's label into additional cardiovascular and metabolic indications remains active in the pipeline, with additional SURMOUNT-program readouts expected.

Outlook

Shaq Zepbound partnership represents Eli Lilly's most prominent direct-to-consumer push into the tirzepatide sleep apnea indication to date. With clinical evidence showing dramatic reductions in OSA severity and a vast undiagnosed population, the campaign is positioned to accelerate both disease awareness and prescription volume. Lilly's tirzepatide franchise continues to define the competitive landscape in GLP-1 therapeutics heading into the second half of 2026. Mentioned tickers: LLY, NVO

Health